UCB dedicated its future U.S. biologics manufacturing campus in Rowen, Georgia, marking a major step in expanding capacity for current and next-generation biologics. The planned $2 billion site is expected to support commercial production as early as the early 2030s and is designed to integrate AI, automation, and advanced manufacturing methods. UCB said the campus will create about 330 permanent jobs and occupy roughly 79 acres within the Rowen innovation district. The announcement highlights local incentives—Georgia’s Gwinnett County committed $174 million in infrastructure and incentives—alongside the company’s long-term patient-service strategy. This move is notable for biotech manufacturing planning because it locks in multi-year capacity and process-learning cycles in a single hub. It also underscores how the US is competing for biologics scale-up beyond clinical development, with practical manufacturing readiness increasingly shaping where developers want to locate supply chains.